Understanding therapeutic pathways and comorbidities in psoriasis.

Kenneth B. Gordon*, Bruce E. Strober

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Psoriasis is now recognized as an immunologically mediated systemic disease that may be expressed in cutaneous and joint symptoms. Medications that were once thought to control psoriasis by reducing keratinocyte proliferation are now known to act on immunologic pathways. In recent years, the emerging understanding of immunologic pathways in psoriasis has resulted in the use of biologic medications (eg, inhibitors of tumor necrosis factor) to treat psoriasis. More recently, other pathophysiologic pathways have been identified that have the potential to expand the therapeutic armamentarium. Other avenues of research within the past decade have demonstrated that a range of health risks and comorbid inflammatory diseases are associated with psoriasis, and they have the potential to increase morbidity and mortality and adversely affect quality of life. 2014 published by Frontline Medical Communications.

Original languageEnglish (US)
Pages (from-to)S20-23
JournalSeminars in cutaneous medicine and surgery
Issue number2 Suppl 2
StatePublished - Mar 2014

ASJC Scopus subject areas

  • Surgery
  • Dermatology


Dive into the research topics of 'Understanding therapeutic pathways and comorbidities in psoriasis.'. Together they form a unique fingerprint.

Cite this